NCT03284164View on ClinicalTrials.gov

Evaluation of Effect of Renal Impairment on the PK of Tenofovir Exalidex

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 28, 2017

Primary Completion Date

January 17, 2018

Study Completion Date

February 20, 2018

Conditions
Renal Impairment
Interventions
DRUG

Tenofovir Exalidex (TXL)

Drug: Tenofovir Exalidex (TXL)

Trial Locations (1)

32809

Orlando Clinical Research Center, Orlando

Sponsors
All Listed Sponsors
lead

ContraVir Pharmaceuticals, Inc.

INDUSTRY